{"id":"8770555a-dbd5-5971-b28f-81a8bdfed935","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-variation-is-enormous","predicate":"modulates","statement":"In twelve patients given 10 milligrams per kilogram for cystic hydatid disease the plasma concentration-time profiles differed considerably, with elimination half-lives from 2.8 to 9.0 hours, time to peak from 1.5 to 7.25 hours and peak concentrations from 17.5 to 500 nanograms per millilitre, and the mean peak after an initial dose of 69.5 nanograms per millilitre was lower than during chronic therapy at 137.4 nanograms per millilitre.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"8cb13dc4-5d9f-5489-a288-4e570e940bf7","mechanism_event_label":"The same dose gives one patient thirty times the blood level of another.","subject":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"object":{"id":"42246bab-bc05-54aa-bed7-28c5ea57976c","slug":"plasma-concentration","display_name":"Plasma concentration of mebendazole","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"8cb13dc4-5d9f-5489-a288-4e570e940bf7","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-variation-is-enormous-event","event_type":"observed_intervention","label":"The same dose gives one patient thirty times the blood level of another.","description":"In twelve patients given 10 milligrams per kilogram for cystic hydatid disease the plasma concentration-time profiles differed considerably, with elimination half-lives from 2.8 to 9.0 hours, time to peak from 1.5 to 7.25 hours and peak concentrations from 17.5 to 500 nanograms per millilitre, and the mean peak after an initial dose of 69.5 nanograms per millilitre was lower than during chronic therapy at 137.4 nanograms per millilitre.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c42f1791-ecdc-584a-b45d-99dc23ededff","slug":"oral-bioavailability","display_name":"Oral bioavailability","entity_type_key":"cellular_process"},"role":"underlying_cause","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"42246bab-bc05-54aa-bed7-28c5ea57976c","slug":"plasma-concentration","display_name":"Plasma concentration of mebendazole","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/7094986.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd\", \"start_char\": 0, \"end_char\": 1256, \"text_sha256\": \"5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Plasma monitoring of mebendazole and its metabolites in twelve patients treated for cystic hydatid disease","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"10 milligrams per kilogram, with tissue sampled at surgery in two patients","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Twelve patients with wide between-patient variation. The enterohepatic recycling explanation is the authors’ inference from the metabolite profile.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The same dose gives one patient thirty times the blood level of another.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p7094986] Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. (1982). https://pubmed.ncbi.nlm.nih.gov/7094986/ DOI: 10.1007/bf00542462","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Plasma, tissue and cyst material","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"cd76176a-f61c-5e3d-959a-9284cc0bad45","evidence_kind":"source_excerpt","locator":"Lines 433-444","start_line":433,"end_line":444,"excerpt":"### mbz-variation-is-enormous\nIn twelve patients given 10 milligrams per kilogram for cystic hydatid disease the plasma concentration-time profiles differed considerably, with elimination half-lives from 2.8 to 9.0 hours, time to peak from 1.5 to 7.25 hours and peak concentrations from 17.5 to 500 nanograms per millilitre, and the mean peak after an initial dose of 69.5 nanograms per millilitre was lower than during chronic therapy at 137.4 nanograms per millilitre.\nCondition category: normal\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: The same dose gives one patient thirty times the blood level of another.\norganism: Human\ntissue_or_cell_type: Plasma, tissue and cyst material\nexperimental_model: Plasma monitoring of mebendazole and its metabolites in twelve patients treated for cystic hydatid disease\nlimitations: Twelve patients with wide between-patient variation. The enterohepatic recycling explanation is the authors’ inference from the metabolite profile.\nexposure: 10 milligrams per kilogram, with tissue sampled at surgery in two patients\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/7094986.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd\", \"start_char\": 0, \"end_char\": 1256, \"text_sha256\": \"5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd\"}\n[mbz-p7094986] Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. (1982). https://pubmed.ncbi.nlm.nih.gov/7094986/ DOI: 10.1007/bf00542462","model_system":"Plasma monitoring of mebendazole and its metabolites in twelve patients treated for cystic hydatid disease","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p7094986] Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. (1982). https://pubmed.ncbi.nlm.nih.gov/7094986/ DOI: 10.1007/bf00542462","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}